SNS Insider projected that the global peptide-drug conjugate market will grow from $3.85 billion in 2025 to $15.05 billion by 2035. The September 9 forecast implies a 14.6% compound annual growth rate, driven mainly by oncology products and the expansion of radioligand therapies, according to the report distributed through GlobeNewswire.
That headline figure is a commercial projection, not a regulatory milestone or a tally of signed contracts. SNS Insider does not publish the underlying source data or full segmentation method in the release. The estimate is therefore most useful as a view of where analysts expect demand to concentrate, rather than as a verified measure of future revenue.
Radioligands anchor the forecast
Figure 1: Projected growth trajectory for the peptide-drug conjugate market through 2035 with oncology and radioligand emphasis.
Peptide-drug conjugates use a peptide as a targeting component linked to a cytotoxic, radioactive, or otherwise active payload. The commercial premise is selective delivery: the peptide binds to a receptor associated with diseased tissue and carries the payload toward that target. This mechanism separates the category from the broader market for unconjugated therapeutic peptides and from metabolic medicines covered in our GLP-1, GIP and glucagon multi-agonist comparison.
The report identifies therapeutic radiopharmaceuticals and diagnostic agents as the sector's commercial base. Existing products, including Pluvicto and Lutathera, provide revenue precedents for targeted radioligand treatment. The forecast assumes that additional indications and earlier use in cancer care will enlarge the eligible patient population. It also points to Illuccix as an example of diagnostic demand within the same broad market.
Geography matters to the model. Europe accounted for an estimated 27% of the 2025 market, or $1.04 billion, and is projected to reach $3.72 billion by 2035 at a 13.6% annual growth rate, the SNS Insider release states. North America is described as the largest regional market, supported by oncology infrastructure and existing radiopharmaceutical adoption.
The engineering constraints behind the growth curve
The same mechanism that gives a conjugate its targeting potential creates development risks. Peptides can be cleared rapidly by the kidneys, while an unstable linker may release its payload before the compound reaches the intended tissue. Manufacturing must also control the peptide, linker, payload and final conjugate consistently. Those requirements make scale-up more complicated than a simple increase in peptide synthesis capacity.
The report cites the withdrawal of Pepaxto after post-marketing safety concerns as a reminder that commercial availability does not eliminate clinical risk. Pipeline growth must still survive safety monitoring, manufacturing validation and regulatory review. Readers comparing these assets with metabolic products can use our guide to weight-loss peptide clinical mechanisms to distinguish receptor agonists from targeted conjugates.
What the $15 billion figure does and does not show
The forecast describes a plausible growth path if radioligand indications expand and new conjugate platforms reach the market. It does not establish that every announced program will succeed, that reimbursement will follow approval, or that manufacturing capacity will arrive on schedule. It also gives investors no public sensitivity analysis showing how the total changes if a major oncology asset fails.
The useful signal is narrower than the headline: analysts expect peptide targeting to capture a larger role in precision oncology, and existing radiopharmaceutical products give that thesis a commercial foundation. The exact 2035 total remains an estimate whose assumptions should be tested against approvals, trial readouts and disclosed sales as those events occur.
